ANDA 202859, held by PharmoBedient. Montelukast Sodium.
As of Nov 21, 2026, ANDA 202859 (Montelukast Sodium), held by PharmoBedient, was first approved by FDA on Oct 30, 2014, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 30, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Montelukast SodiumEQ 10MG BASE ยท tablet;oral | Montelukast Sodium | Rx |
| Dec 8, 2015 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Jun 25, 2015 | Supplement 2Manufacturing | Approved | None posted |
| Mar 20, 2015 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Mar 20, 2015 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Mar 20, 2015 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Oct 30, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters